IP Library Granted Patent US 11,951,183
Granted Patent B2
US 11,951,183 · App. 16/824,008 · Granted Apr 9, 2024

Adeno-associated virus compositions for PAH gene transfer and methods of use thereof

Inventors: Albert Barnes Seymour (Westborough, MA); Seemin Seher Ahmed (Worcester, MA); Jason Boke Wright (Concord, MA); Serena Nicole Dollive (Waltham, MA); Hillard Rubin (Northborough, MA)
Assignee: HOMOLOGY MEDICINES, INC.
A61K48/0066C12N15/86C12N2750/14143C12N2750/14152C12N2750/14171C12N2830/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,951,183
App. No.
16/824,008
Granted
Apr 9, 2024
Kind
B2
Abstract

Provided herein are adeno-associated virus (AAV) compositions that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell, thereby restoring the PAH gene function. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

Claims (25)

1. A packaging system for preparation of a replication-defective AAV comprising:

(a) a first nucleotide sequence comprising a first transcriptional regulatory element operably linked to a nucleotide sequence encoding one or more AAV Rep proteins;

(b) a second nucleotide sequence comprising a second transcriptional regulatory element operably linked to a nucleotide sequence encoding an AAV capsid protein; and

(c) a third nucleotide sequence comprising a transfer genome comprising, from 5′ to 3′:

(i) an AAV2 5′ inverted terminal repeat (ITR) nucleotide sequence;

(ii) a transcriptional regulatory element comprising, from 5′ to 3′, a human hepatic control region 1 (HCR1) and a human al-antitrypsin (hAAT) promoter;

(iii) a silently altered PAH coding sequence having at least 80% sequence identity to the nucleotide sequence of SEQ ID NO: 71, wherein the silently altered PAH coding sequence encodes the amino acid sequence set forth in SEQ ID NO: 23; and

(iv) an AAV2 3′ ITR nucleotide sequence.

2. A method for producing a replication-defective AAV, the method comprising introducing the packaging system of claim 1 into a cell under conditions operative for producing the AAV.

3. The packaging system of claim 1 , wherein the packaging system comprises a first vector comprising the first nucleotide sequence and the second nucleotide sequence, and a second vector comprising the third nucleotide sequence.

4. The packaging system of claim 3 , further comprising a third vector, wherein the third vector is a helper virus vector.

5. The packaging system of claim 4 , wherein the helper virus vector is an independent third vector.

6. The packaging system of claim 4 , wherein the third vector comprises genes encoding helper virus proteins.

7. The packaging system of claim 4 , wherein the helper virus is selected from the group consisting of adenovirus, herpes virus, vaccinia virus, and cytomegalovirus (CMV).

8. The packaging system of claim 7 , wherein the helper virus is adenovirus.

9. The packaging system of claim 8 , wherein the adenovirus genome comprises one or more adenovirus RNA genes selected from the group consisting of E1, E2, E4 and VA.

10. The packaging system of claim 7 , wherein the helper virus is herpes simplex virus (HSV).

11. The packaging system of claim 10 , wherein the HSV genome comprises one or more HSV genes selected from the group consisting of UL5/8/52, ICPO, 1CP4, ICP22 and UL30/UL42.

12. The packaging system of claim 4 , wherein the first vector and the third vector are contained within a first transfecting plasmid.

13. The packaging system of claim 4 , wherein the nucleotide sequences of the second vector and the third vector are contained within a second transfecting plasmid.

14. The packaging system of claim 4 , wherein the nucleotide sequences of the first vector and the third vector are cloned into a recombinant helper virus.

15. The packaging system of claim 4 , wherein the nucleotide sequences of the second vector and the third vector are cloned into a recombinant helper virus.

16. The packaging system of claim 1 , wherein the Rep nucleotide sequence encodes an AAV2 Rep protein.

17. The packaging system of claim 16 , wherein the AAV2 Rep protein is Rep 78/68 or Rep 68/52.

18. The packaging system of claim 16 , wherein the AAV2 Rep protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 22.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2025
From: Q32 BIO, INC.
To: CITY OF HOPE
Reel/Frame 070700/0903 →
CHANGE OF NAME Recorded Mar 18, 2025
From: HOMOLOGY MEDICINES, INC.
To: Q32 BIO INC.
Reel/Frame 070542/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2020
From: SEYMOUR, ALBERT BARNES; AHMED, SEEMIN SEHER; WRIGHT, JASON BOKE; DOLLIVE, SERENA NICOLE; RUBIN, HILLARD
To: HOMOLOGY MEDICINES, INC.
Reel/Frame 053057/0979 →
Continuity (4)
Division 16369879 · Mar 29, 2019
Continuation PCTUS2019016351 · Feb 1, 2019
Provisional Application 62625150 · Feb 1, 2018
Related Publication 20200316223A1 · Oct 8, 2020